Freeline nabs $120M, eyes IPO as its gene therapy comes into focus
Freeline Therapeutics has landed another mega-round to back its gene therapy efforts and, on the same morning of the announcement, indicated that they could yet raise significantly more cash before year’s end.
The new Series C rings in at $120 million, a hair above their $112 million Series B in 2018. And for the first time since Freeline’s launch, the round includes prominent investors outside of their founding VC, Syncona, including Novo Holdings, Eventide Asset Management and Wellington Management Company. The new investors are joining as the first clinical data emerge for the company, with Freeline also saying today they would present data showing their lead drug could bring factor IX to normal in severe hemophilia patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 91,900+ biopharma pros reading Endpoints daily — and it's free.